(6) Cetin, K., Ettinger, D., & O'Malley, C. (2011). Survival by histologic subtype in stage IV nonsmall cell lung cancer based on data from the Surveillance, Epidemiology and End Results Program. Clinical Epidemiology CLEP,3. doi:10.2147/CLEP.S17191.
(7) Oliver, T., Patel, J., & Akerley, W. (2015). Squamous Non-small Cell Lung Cancer as a Distinct Clinical Entity. American Journal of Clinical Oncology, 18 Dic. (2) - , 220-226. doi:10.1097/COC.0b013e3182a0e850.
(8) Baselga J. (2002) Why the epidermal growth factor receptor? The rationale for cancer therapy. Oncologist, 7(suppl 4):2-8.
Refer to:Crystal Livers-Powers; crystal_livers-powers@lilly.com[mailto:crystal_livers-powers@lilly.com]; (317) 476-4160 (Lilly Oncology) Mariann Caprino; m.caprino@togorun.com[mailto:m.caprino@togorun.com]; +1 (917) 242-1087 (TogoRun)
Logo -- http://photos.prnewswire.com/prnh/200312... [http://photos.prnewswire.com/prnh/200312...]
Web site: http://www.lilly.com/
